

LIST OF PATENTS AND PUBLICATIONS FOR
APPLICANT'S INFORMATION DISCLOSURE
STATEMENTATTY. DOCKET NO.
18810-82302SERIAL NO.
UNASSIGNED
09/898,779

APPLICANT: KENT D. TAYLOR ET AL.

FILING DATE: HEREWITH

GROUP ART UNIT NO. 1655

U.S. PAT. & TM. OFF.
09/898,779
07/03/01

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE
gy	4,683,195	07/28/87	Mullis et al.			
	4,683,202	07/28/87	Mullis			
	4,988,617	91/29/91	Landegren			
	5,384,242	01/24/95	Oakes			

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	Translation	
					YES	NO

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

gy	1.	Anguita, M. et al., <i>Comparison of the effectiveness of lovastatin therapy for hypercholesterolemia after heart transplantation between patients with and without pretransplant atherosclerotic coronary artery diseases</i> , <u>Am. J. Cardiol.</u> , 74(8):776-779 (Oct. 15, 1994).
	2.	Alván, Gunnar, <i>Editorial, Genetic polymorphisms in drug metabolism</i> , <u>Journal of Internal Medicine</u> , Vol. 231, pp. 571-573, (1992).
	3.	Ballantyne, C. M., <i>Low-density lipoproteins and risk for coronary artery disease</i> , <u>Am. J. Cardiol.</u> , 82(9A):3Q-12Q (Nov 5, 1998).
	4.	Bell, D. S., <i>A comparison of lovastatin, an HMG-CoA reductase inhibitor, with gemfibrozil, a fibrinic acid derivative, in the treatment of patients with diabetic dyslipidemia</i> , <u>Clin Ther.</u> 17(5):901-910 (Sep 1995) ABSTRACT ONLY.

EXAMINER

J. Goldberg

DATE CONSIDERED

1/9/02

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (Modified)

ATTY. DOCKET NO.

18810-82302

SERIAL NO.

UNASSIGNED

LIST OF PATENTS AND PUBLICATIONS FOR
APPLICANT'S INFORMATION DISCLOSURE
STATEMENT

APPLICANT: KENT D. TAYLOR ET AL.

FILING DATE: HEREWITH

GROUP ART UNIT NO. - -

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

5.	Bellosta, S. et al., <i>HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages</i> , <i>Arterioscler Thromb Vasc Biol</i> , 18(11):1671-8 (Nov 1998).
6.	Butowski, P.F. et al., <i>Usual care dietary practice, achievement and implications for medication in the management of hypercholesterolaemia. Data from the U.K. Lipid Clinics Programme.</i> , <i>Eur Heart J.</i> , 19(9):1328-33 (Sep 1998).
7.	Campeau, Lucien et al., <i>The Relation of Risk Factors to the Development of Atherosclerosis in Saphenous-vein Bypass Grafts and the Progression of Disease in the Native Circulation</i> , <i>The New England Journal of Medicine</i> , Vol. 311, No. 21, pp. 1329-32 (Nov 22, 1984).
8.	Campeau, Lucien et al., <i>The Effect of Aggressive Lowering of Low-Density Lipoprotein Cholesterol Levels and Low-Dose Anticoagulation on Obstructive Changes in Saphenous-vein Coronary-Artery Bypass Grafts</i> , <i>The New England Journal of Medicine</i> , Vol. 336, No. 3, pp. 153-162 (Jan 16, 1997).
9.	Cannon, C. P., <i>Advances in the medical management of acute coronary syndromes</i> , <i>Curr Opin Cardiol</i> , 13(5):327-47 (Sep 1998). ABSTRACT ONLY.
10.	Chen, L. et al., <i>HindIII DNA polymorphism in the lipoprotein lipase gene and plasma lipid phenotypes and carotid artery atherosclerosis</i> , <i>Hum Genet</i> , 98(5):551-556 (Nov 1996).
11.	Chuat, J. C. et al., <i>The lipoprotein lipase-encoding human gene: sequence from intron-6 to intron-9 and presence in intron-7 of a 40-million-year-old Alu sequence</i> , <i>Gene</i> , 110(2):257-61 (Jan 15, 1992). ABSTRACT ONLY.
12.	Clark, A. G. et al., <i>Haplotype structure and population genetic inferences from nucleotide-sequence variation in human lipoprotein lipase</i> , <i>Am J. Hum Genet</i> , 63(2):595-612 (Aug 1998).
13.	Deeb, Samir S., et al., <i>Structure of the Human Lipoprotein Lipase Gene</i> , <i>Biochemistry</i> , Vol. 28, No. 10, pp. 4131-35 (May 16, 1989).
14.	Durrington, P. N., <i>Can we afford to treat hyperlipidaemia as we should? Strategies for rational treatment</i> , <i>Atherosclerosis</i> , 139 Suppl 1:S1-5 (Sep 1998). ABSTRACT ONLY.
15.	Farmer, J. A. et al., <i>Currently available hypolipidaemic drugs and future therapeutic developments</i> , <i>Baillieres Clin Endocrinol Metab</i> , 9(4):825-847 (Oct 1995).

EXAMINER

DATE CONSIDERED

J. Goldberg

1/9/02

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

7316.1

FORM PTO-1449 (Modified)

ATTY. DOCKET NO.
18810-82302SERIAL NO. :
UNASSIGNEDLIST OF PATENTS AND PUBLICATIONS FOR
APPLICANT'S INFORMATION DISCLOSURE
STATEMENT

APPLICANT: KENT D. TAYLOR ET AL.

FILING DATE: HEREWITH

GROUP ART UNIT NO. - -

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

16.	Farmer, J. A. et al., <i>Choosing the right lipid-regulating agent. A guide to selection</i> , <u>Drugs</u> , 52(5):649:661 (Nov 1996).
17.	Farmer, J. A., <i>Economic implications of lipid-lowering trials: current considerations in selecting a statin</i> , <u>Am J. Cardiol</u> , 82(6A):26M-31M (Sep 24 1998).
18.	Farmer, J. A., <i>Aggressive lipid therapy in the statin era</i> , <u>Prog Cardiovasc Dis</u> , 41(2):71-94 (Sep-Oct 1998).
19.	Farnier, M. et al., <i>Current and future treatment of hyperlipidemia: the role of statins</i> , <u>Am J. Cardiol</u> , 82(48):3J-10J (Aug 27, 1998).
20.	Fisher, R. M. et al., <i>Common variation in the lipoprotein lipase gene: effects on plasma lipids and risk of atherosclerosis</i> , <u>Atherosclerosis</u> , 135(2):145-59 (Dec 1997). ABSTRACT ONLY.
21.	Funke Harald et al., <i>The low down on lipoprotein lipase</i> , <u>Nature Genetics</u> , Vol. 10, pp. 6-7 (May 1995).
22.	Garg, A. et al., <i>Lovastatin for lowering cholesterol levels in non-insulin-dependent diabetes mellitus</i> , <u>N Engl J. Med</u> , 318(2):81-86 (Jan 1988).
23.	Gerdes, C. et al., <i>Polymorphisms in the lipoprotein lipase gene and their associations with plasma lipid concentrations in 40-year-old Danish men</i> , <u>Circulation</u> , 92(7):1765-1769 (Oct 1995).
24.	Goldberg, R. et al., <i>Comparison of the effects of lovastatin and gemfibrozil on lipids and glucose control in non-insulin-dependent diabetes mellitus</i> , <u>Am J Cardiol</u> , 66(8):16B-21B (Sep 18, 1990).
25.	Guyton, J. R., et al., <i>Effectiveness of once-nightly dosing of extended-release niacin alone and in combination for hypercholesterolemia</i> , <u>Am J Cardiol</u> , 82(6):737-43 (Sep 15, 1998).
26.	Gylling, H. et al., <i>Treatment of lipid disorders in non-insulin-dependent diabetes mellitus</i> , <u>Curr Opin Lipidol</u> , 8(6):342-7 (Dec 1997).
27.	Hansson, L. et al., <i>Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group</i> , <u>Lancet</u> , 351(9118):1755-62 (Jun 13, 1998).
28.	Hayden, M. R. et al., <i>Molecular genetics of human lipoprotein lipase deficiency</i> , <u>Mol Cell Biochem</u> , 113(2):171-176 (Aug 18, 1992).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

7316.1

FORM PTO-1449 (Modified)

ATTY. DOCKET NO.
18810-82302SERIAL NO.
UNASSIGNEDLIST OF PATENTS AND PUBLICATIONS FOR
APPLICANT'S INFORMATION DISCLOSURE
STATEMENT

APPLICANT: KENT D. TAYLOR ET AL.

FILING DATE: HEREWITH

GROUP ART UNIT NO. - -

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

29.	Heizmann, Camilla et al., <i>DNA polymorphism haplotypes of the human lipoprotein lipase gene: possible association with high density lipoprotein levels</i> , <u>Human Genetics</u> , Vol. 86, pp. 578-84 (1991).
30.	Humphries, S. E. et al., <i>Lipoprotein lipase gene variation is associated with a paternal history of premature coronary artery disease and fasting and postprandial plasma triglycerides: the European Atherosclerosis Research Study (EARS)</i> , <u>Arterioscler Throm Vasc Biol</u> , 18(4):526-34 (Apr 1998).
31.	Huse, D. M. et al., <i>Cost-effectiveness of statins</i> , <u>Am J. Cardiol</u> , 82(11):1357-63 (Dec 1, 1998).
32.	Jukema, J. Wouter et al., <i>The Asp, Asn Mutation in the Lipoprotein Lipase Gene is Associated with Increased Progression of Coronary Atherosclerosis</i> , <u>Circulation</u> , Vol. 94, No. 8, pp. 1913-18 (Oct 15, 1996).
33.	Kirchgessner, Todd G. et al., <i>The sequence of cDNA Encoding Lipoprotein Lipase</i> , <u>The Journal of Biological Chemistry</u> , Vol. 262, No. 18, pp. 8463-8466 (Jun 25, 1987).
34.	Kirchgessner, T. G. et al., <i>Organization of the human lipoprotein lipase gene and evolution of the lipase gene family</i> , <u>Proc Natl Acad Sci USA</u> , Vol. 86, No. 24, pp. 9647-9651 (Dec 1989).
35.	Kleyn, Patrick W. et al., <i>Genetic Variation as a Guide to Drug Development</i> , <u>Science</u> , Vol. 281, pp. 1820-21 (Sep 18, 1998).
36.	Kornitzer, M., <i>Primary and secondary prevention of coronary artery disease: a follow-up on clinical controlled trials</i> , <u>Curr Opin Lipidol</u> , 9(6):557-64 (Dec 1998). ABSTRACT ONLY.
37.	Kozaki, K. et al., <i>Mutational analysis of human lipoprotein lipase by carboxy-terminal truncation</i> , <u>J Lipid Res</u> , 34(10):1765-1772 (Oct 1993). ABSTRACT ONLY.
38.	Kuivenhoven, Jan Albert et al., <i>The role of a Common Variant of the Cholesteryl Ester Transfer Protein Gene in the Progression of Coronary Atherosclerosis</i> , <u>The New England Journal of Medicine</u> , Vol. 338, No. 2, pp. 86-93 (Jan 8, 1998).
39.	LaRosa, J. C., <i>The role of diet and exercise in the statin era</i> , <u>Prog Cardiovasc Dis</u> , 41(2):137-50 (Sep-Oct 1998).
40.	McKenney, J. M., <i>Lovastatin: a new cholesterol-lowering agent</i> , <u>Clin Pharm</u> , 7(1):21-36 (Jan 1988).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

7316.1

FORM PTO-1449 (Modified)

ATTY. DOCKET NO.

18810-802302

SERIAL NO.

UNASSIGNED

LIST OF PATENTS AND PUBLICATIONS FOR
APPLICANT'S INFORMATION DISCLOSURE
STATEMENT

APPLICANT: KENT D. TAYLOR ET AL.

FILING DATE: HERewith

GROUP ART UNIT NO. - -

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

41.	Mori, A. et al., <i>Development of a direct DNA sequencing method for detecting heterozygous mutations of the human lipoprotein lipase gene</i> , <u>Clin Biochem</u> , 30(4):315-324, (Jun 1997). ABSTRACT ONLY.
42.	Neitzel, Gary F. et al., <i>Atherosclerosis in Aortocoronary Bypass Grafts, Morphologic Study and Risk Factor Analysis 6 to 12 Years After Surgery</i> , <u>Arteriosclerosis</u> , Vol. 6, No. 6, pp. 594-600 (Nov/Dec 1986).
43.	Nickerson, Deborah A. et al., <i>DNA sequence diversity in a 9.7-kb region of the human lipoprotein lipase gene</i> , <u>Nature Genetics</u> , Vol. 19, No. 3, pp. 233-240 (Jul 1998).
44.	Oka, Kazuhiro et al., <i>Structure and polymorphic map of human lipoprotein lipase gene</i> , <u>Biochimica et Biophysica Acta</u> , Vol. 1049, pp. 21-26 (1990).
45.	Olsson, A. G., <i>Addressing the challenge</i> , <u>Eur Heart J</u> , 19 Suppl M: M29-35 (Oct 1998).
46.	Peacock, Rachel E. et al., <i>Associations between lipoprotein lipase gene polymorphisms and plasma correlations of lipids, lipoproteins and lipase activities in young myocardial infarction survivors and age-matched healthy individuals from Sweden</i> , <u>Atherosclerosis</u> , Vol. 97, pp. 171-185 (1992).
47.	Pedersen, T. R. et al., <i>Benefits and risks of HMG-CoA reductase inhibitors in the prevention of coronary heart disease: a reappraisal</i> , <u>Drug Saf</u> , 14(1):11-24 (Jan 1996). ABSTRACT ONLY.
48.	Pitsavos, C. E. et al., <i>Effects of pravastatin on thoracic aortic atherosclerosis in patients with heterozygous familial hypercholesterolemia</i> , <u>Am J Cardiol</u> , 82(12):1484-8 (Dec 15, 1998).
49.	Reymer, P. W. et al., <i>A lipoprotein lipase mutation (Asn291Ser) is associated with reduced HDL cholesterol levels in premature atherosclerosis</i> , <u>Nat Genet</u> , 10(1):28-34 (May 1995).
50.	Rifkind, B. M., <i>Clinical trials of reducing low-density lipoprotein concentrations</i> , <u>Endocrinol Metab Clin North Am</u> , 27(3):585-95, viii-ix (Sep 1998). ABSTRACT ONLY.
51.	Rudski, L. et al., <i>Systemic immune reactions to HMG-CoA reductase inhibitors. Report of 4 cases and review of the literature</i> , <u>Medicine (Baltimore)</u> , 77(6):378-83 (Nov 1998). ABSTRACT ONLY.

EXAMINER

J. Goldberg

DATE CONSIDERED

1/9/02

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

7316.1

FORM PTO-1449 (Modified)

ATTY. DOCKET NO.
18810-82302SERIAL NO.
UNASSIGNEDLIST OF PATENTS AND PUBLICATIONS FOR
APPLICANT'S INFORMATION DISCLOSURE
STATEMENT

APPLICANT: KENT D. TAYLOR ET AL.

FILING DATE: HEREWITH

GROUP ART UNIT NO. - -

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

52.	Santamarina-Fojo, Silvia et al., <i>Structure, function and role of lipoprotein lipase in lipoprotein metabolism</i> , <u>Genetics and Molecular Biology</u> , <u>Current Opinion in Lipidology</u> , Vol.5, pp. 117-125 (1994).
53.	Sass, C. et al., <i>Evidence for a cholesterol-lowering gene in a French-Canadian kindred with familial hypercholesterolemia</i> , <u>Hum Genet</u> , 96(1):21-26 (Jul 1995).
54.	Scheen, A. J., <i>[Drug clinics. Drug of the month. Atorvastatin]</i> , <u>Rev Med Liege</u> , 53(6):374-7 (June 1998). ABSTRACT ONLY.
55.	Szucs, T. D., <i>Pharmaco-economic aspects of lipid-lowering therapy: is it worth the price?</i> , <u>Eur Heart J</u> , 19 Suppl M:M22-8 (Oct 1998).
56.	Tikkanen, M. J. et al., <i>Treatment of familial and non-familial hypercholesterolaemia: a review of HMG-CoA reductase inhibitors and probucol</i> , <u>Eur Heart J</u> , 8 Suppl E: 97-101 (Aug 1987). ABSTRACT ONLY.
57.	The Medical Research Council's General Practice Research Framework, <i>Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. The Medical Research Council's General practice Research Framework</i> , <u>Lancet</u> , 351(9098):233-41 (Jan 24 1998).
58.	Vesell, Elliot S., <i>Therapeutic Lessons from Pharmacogenetics</i> , <u>Annals of Internal Medicine</u> , Vol. 126, No. 8, pp. 653-5 (Apr 15, 1997).
59.	von Keutz, E. et al., <i>Preclinical safety evaluation of cerivastatin, a novel HMG-CoA reductase inhibitor</i> , <u>Am J. Cardiol</u> , 82(4B):11J-17J (Aug 27, 1998).
60.	Weinshilboum, Richard, <i>Methyltransferase Pharmacogenetics</i> , <u>Pharmac Ther</u> , Vol. 43, pp. 77-90 (1989).
61.	Wheeler, D. C., <i>Are there potential non-lipid-lowering uses of statins?</i> , <u>Drugs</u> , 56(4):517-22 (Oct 1998).
62.	Wion, Karen L. et al., <i>Human Lipoprotein Lipase complementary DNA Sequence</i> , <u>Science</u> , Vol. 235, pp. 1638-41 (Mar 27, 1987).
63.	Zuliani, Giovanni et al., <i>Tetranucleotide repeat polymorphism in the LPL gene</i> , Department of Molecular Genetics, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75235 USA (1990).

EXAMINER

J. Goldberg

DATE CONSIDERED

1/9/02

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

7316.1

FORM PTO-1449 (Modified)

ATTY. DOCKET NO.
18810-82302SERIAL NO.
UNASSIGNEDLIST OF PATENTS AND PUBLICATIONS FOR
APPLICANT'S INFORMATION DISCLOSURE
STATEMENT

APPLICANT: KENT D. TAYLOR ET AL.

FILING DATE: HEREWITH

GROUP ART UNIT NO. - -

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	64.	Ahn, Y. I. Et al., Two DNA polymorphisms in the lipoprotein lipase gene and their associations with factors related to cardiovascular disease, J Lipid Res, 34(3):421-8 (Mar 1993). ABSTRACT ONLY. Sup W #70
84	65.	Chamberlain, J.C. et al., DNA polymorphisms at the lipoprotein lipase gene: associations in normal and hypertriglyceridaemic subjects, <u>Atherosclerosis</u> , 79(1):85-91 (Sep 1989).
	66.	Georges, J. L. et al., Family study of lipoprotein lipase gene polymorphisms and plasma triglyceride levels, <u>Genet epidemiol</u> , 13(2):179-92 (1996).
	67.	Mitchell, R. J. et al., DNA polymorphisms at the lipoprotein lipase gene and their association with quantitative variation in plasma high-density lipoproteins and triacylglycerides, <u>Hum Biol</u> , 66(3):383-97 (Jun 1994). ABSTRACT ONLY
	68.	Minnich A. et al., Lipoprotein lipase gene mutations in coronary artery disease, <u>Can J. Cardiol</u> , 14(5):711-6 (May 1998). ABSTRACT ONLY.
	69.	Templeton, A. R. et al., "Recombinational and mutational hotspots within the human lipoprotein lipase gene," <u>Am. J. Hum. Genet.</u> , 66(15):69-83 (2000)
↓	70.	Ahn, Y. I. et al., "Two DNA polymorphisms in the lipoprotein lipase and their associations with factors related to cardiovascular disease," <u>J Lipid Res</u> , 34(8):421-428 (1993)
	71.	Chamberlain, J. C. et al., "DNA polymorphisms at the lipoprotein lipase gene associations in normal and hypertriglycerides subjects," <u>Atherosclerosis</u>, 79(1):85-91 ABSTRACT ONLY (1989) Sup W #65

EXAMINER

g. Goldberg

DATE CONSIDERED

1/9/02

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

7316.1